EIF2A and cancer: Several laboratories, including ours, have employed salubrinal and phosphomimetic [S51D] eIF2α to show that a sustained increase in PeIF2α decreases survival in cancer cells and increases their sensitivity to antineoplastic treatments [10, 49, 50, 51, 52, 53, 54].